Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Looking for short term gigs? Discover where to find quick cash options that fit your schedule.
25,797 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
A six-year milestone in a celebrity marriage invites more than romance headlines. This article uses the Brooklyn Beck...
A rare cross‑party proposal would remove the payroll tax cap to boost funding for Social Security. If enacted, the pl...
Oracle's AI strategy is under scrutiny as earnings shed light on backlog and cash needs. We see roughly 46-47% upside...
As token prices falter, traders are eyeing crypto-linked equities as the potential catalyst for the next crypto recov...
Charter Communications is weighing a potential partnership with SpaceX’s Starlink as it eyes wireless expansion. The ...
A top wall street billionaire turned investor stretched a routine intro with a media cofounder into a full-day sessio...
As July opens, a low-cost dividend ETF stands out for a $2,000 allocation. This report breaks down why it’s considere...
AI funding is surging in 2026, signaling a new investment wave. Here's how an investor ahead next investment can posi...
A free cash flow ETF is delivering a surprising edge in 2026, outperforming the S&P 500 as investors rotate toward ca...
A late-life mortgage decision that looked smart on math may falter when survivorship risk hits the household budget. ...
Tesla shares rise on stronger robotaxi momentum and robust delivery data, sparking a broader EV rally as Rivian, Luci...